FTLF: FitLife Brands, Inc. Stock

by  •  • Comments Off on FTLF: FitLife Brands, Inc. Stock

SIC 2833 – Medicinal Chemicals and Botanical Products

Valuation
Market Cap ($M) 141.26
Enterprise Value ($M) 150.76
Book Value ($M) 34.16
Book Value / Share 7.43
Price / Book 4.14
NCAV ($M) -6.33
NCAV / Share -1.38
Price / NCAV -22.32

Profitability (mra)
Return on Invested Capital (ROIC) 0.17
Return on Assets (ROA) 0.15
Return on Equity (ROE) 0.31

Liquidity (mrq)
Quick Ratio 0.64
Current Ratio 1.50

Balance Sheet (mrq) ($M)
Current Assets 18.10
Assets 58.59
Liabilities 24.43
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-17 13G Askeladden Capital Management Llc

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-04-22 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPO
2024-03-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-03 3,659 15,722 23.27
2025-01-31 1,043 8,054 12.95
2025-01-30 236 3,132 7.54
2025-01-29 578 1,123 51.47

(click for more detail)

Similar Companies
FBRX – Forte Biosciences, Inc. FENC – Fennec Pharmaceuticals Inc.
FLGC – Flora Growth Corp. GALT – Galectin Therapeutics Inc.
GDTC – CytoMed Therapeutics Limited


Financial data and stock pages provided by
Fintel.io